{"id":"NCT01626885","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia","officialTitle":"A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2012-05","primaryCompletion":"2014-06","completion":"2014-06","firstPosted":"2012-06-25","resultsPosted":"2021-04-13","lastUpdate":"2021-04-13"},"enrollment":42,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"MP-214","otherNames":[]}],"arms":[{"label":"MP-214 1.5-9 mg","type":"EXPERIMENTAL"}],"summary":"The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with receiving multiple drugs schizophrenia.","primaryOutcome":{"measure":"Number of Participants With Adverse Events as a Measure of Safety and Tolerability","timeFrame":"Up to 60 weeks","effectByArm":[{"arm":"MP-214 1.5-9 mg","deltaMin":42,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":42},"commonTop":["Nasopharyngitis","Schizophrenia","Headache","Somnolence","Blood creatine phosphokinase increased"]}}